Targeting the progression of Parkinson's disease

Current Neuropharmacology

Volumn 7, Issue 1, 2009, Pages 9-36

  George, J L ^a   Mok, S ^a   Moses, D ^b   Wilkins, S ^a   Bush, A I ^a   Cherny, R A ^a   Finkelstein, D I ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Iron; Metallo chemistry; Parkinson's disease; Pathology; Redox chemistry; Review

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 1,4 ALPHA GLUCAN BRANCHING ENZYME; ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; ALUMINUM; COPPER; DJ 1 PROTEIN; DOPAMINE RECEPTOR STIMULATING AGENT; FERRITIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IRON; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MANGANESE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; PARAQUAT; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN ATP13A2; PROTEIN KINASE; PROTEIN PTEN INDUCED PUTATIVE KINASE 1; PROTEIN UCH L1; RASAGILINE; ROTENONE; SELEGILINE; UBIDECARENONE; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOSOMAL RECESSIVE INHERITANCE; BRAIN DEPTH STIMULATION; BRAIN LEVEL; CELL SURVIVAL; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DRUG ABUSE; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; FETAL MESENCEPHALIC TRANSPLANTATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE THERAPY; GLOBUS PALLIDUS; HEREDITY; HUMAN; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; IRON BRAIN LEVEL; IRON CHELATION; IRON INTAKE; IRON TRANSPORT; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROSURGERY; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PALLIDOTOMY; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; TRANSPLANTATION; UBIQUITINATION;

EID: 65949087857     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015909787602814     Document Type: Review

References (453)

1. Parkinson's Disease Study Group. (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med., 328, 176-183.
2. Parkinson's Disease Study Group. (2001) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N. Engl. J. Med., 345, 956-963.
3. Abou-Sleiman, P.M., Healy, D.G., Quinn, N., Lees, A.J., Wood, N.W. (2003) The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol., 54, 283-286.
4. Abou-Sleiman, P.M., Muqit, M.M., McDonald, N.Q., Yang, Y.X., Gandhi, S., Healy, D.G., Harvey, K., Harvey, R.J., Deas, E., Bhatia, K., Quinn, N., Lees, A., Latchman, D.S., Wood, N.W. (2006) A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann. Neurol., 60, 414-419.
5. Agid, Y., Bonnet, A.M., Ruberg, M., Javoy-Agid, F. (1985) Pathophysiology of L-dopa-induced abnormal involuntary movements. Psychopharmacol. Suppl., 2, 145-159.
6. Ahlskog, J.E. (2003) Parkinson's disease: is the initial treatment established? Curr. Neurol. Neurosci. Rep., 3, 289-295.
7. Alam, M., Schmidt, W.J. (2002) Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res., 136, 317-324.
8. Alam, M., Schmidt, W.J. (2004) L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Behav. Brain Res., 153, 439-446.
9. Alam, Z.I., Daniel, S.E., Lees, A.J., Marsden, D.C., Jenner, P., Halliwell, B. (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem., 69, 1326-1329.
10. Alam, Z.I., Jenner, A., Daniel, S.E., Lees, A.J., Cairns, N., Marsden, C.D., Jenner, P., Halliwell, B. (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem., 69, 1196-1203.
11. Alves Da Costa, C., Paitel, E., Vincent, B., Checler, F. (2002) Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J. Biol. Chem., 277, 50980-50984.
12. Anderson, C., Checkoway, H., Franklin, G.M., Beresford, S., Smith-Weller, T., Swanson, P.D. (1999) Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov. Disord., 14, 21-27.
13. Ascherio, A., Chen, H., Weisskopf, M.G., O'Reilly, E., McCullough, M.L., Calle, E.E., Schwarzschild, M.A., Thun, M.J. (2006) Pesticide exposure and risk for Parkinson's disease. Ann. Neurol., 60 197-203.
14. Athanassiadou, A., Voutsinas, G., Psiouri, L., Leroy, E., Polymeropoulos, M.H., Ilias, A., Maniatis, G.M., Papapetropoulos, T. (1999) Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am. J. Hum. Genet., 65, 555-558.
15. Avramovich-Tirosh, Y., Amit, T., Bar-Am, O., Zheng, H., Fridkin, M., Youdim, M.B. (2007) Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem., 100, 490-502.
16. Barbeau, A., Inoue, N., Cloutier, T. (1976) Role of manganese in dystonia. Adv. Neurol., 14, 339-352.
17. Barden, H., Levine, S. (1983) Histochemical observations on rodent brain melanin. Brain Res. Bull., 10, 847-851.
18. Barnham, K.J., Haeffner, F., Ciccotosto, G.D., Curtain, C.C., Tew, D., Mavros, C., Beyreuther, K., Carrington, D., Masters, C.L., Cherny, R.A., Cappai, R., Bush, A.I. (2004) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J., 18, 1427-1429.
19. Bartzokis, G., Beckson, M., Hance, D.B., Marx, P., Foster, J.A., Marder, S.R. (1997) MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn. Reson. Imaging, 15, 29-35.
20. Bartzokis, G., Cummings, J.L., Markham, C.H., Marmarelis, P.Z., Treciokas, L.J., Tishler, T.A., Marder, S.R., Mintz, J. (1999) MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn. Reson. Imaging, 17, 213-222.
21. Bartzokis, G., Tishler, T.A., Shin, I.S., Lu, P.H., Cummings, J.L. (2004) Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann. N. Y. Acad. Sci., 1012, 224-236.
22. Beal, M.F., Matthews, R.T., Tieleman, A., Shults, C.W. (1998) Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res., 783, 109-114.
23. Beilina, A., Van Der Brug, M., Ahmad, R., Kesavapany, S., Miller, D.W., Petsko, G.A., Cookson, M.R. (2005) Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl. Acad. Sci. USA, 102, 5703-5708.
24. Benabid, A.L., Pollak, P., Louveau, A., Henry, S., de Rougemont, J. (1987) Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl. Neurophysiol., 50, 344-346.
25. Ben-Shachar, D., Youdim, M.B. (1991) Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J. Neurochem., 57, 2133-2135.
26. Bergomi, M., Vinceti, M., Nacci, G., Pietrini, V., Bratter, P., Alber, D., Ferrari, A., Vescovi, L., Guidetti, D., Sola, P., Malagu, S., Aramini, C., Vivoli, G. (2002) Environmental exposure to trace elements and risk of amyotrophic lateral sclerosis: a population-based case-control study. Environ. Res., 89, 116-123.
27. Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V., Greenamyre, J.T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci., 3, 1301-1306.
28. Bharathi, Indi, S.S., Rao, K.S. (2007) Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. Neurosci. Lett., 424, 78-82.
29. Bharathi, Rao, K.S. (2007) Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease. Biochem. Biophys. Res. Commun., 359, 115-120.
30. Bjorklund, A., Dunnett, S.B., Brundin, P., Stoessl, A.J., Freed, C.R., Breeze, R.E., Levivier, M., Peschanski, M., Studer, L., Barker, R. (2003) Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol., 2, 437-445.
31. Bjorklund, A., Gage, F.H., Schmidt, R.H., Stenevi, U., Dunnett, S.B. (1983) Intracerebral grafting of neuronal cell suspensions. VII. Recovery of choline acetyltransferase activity and acetylcholine synthesis in the denervated hippocampus reinnervated by septal suspension implants. Acta Physiol. Scand. Suppl., 522, 59-66.
32. Bjorklund, A., Gage, F.H., Stenevi, U., Dunnett, S.B. (1983) Intracerebral grafting of neuronal cell suspensions. VI. Survival and growth of intrahippocampal implants of septal cell suspensions. Acta Physiol. Scand. Suppl., 522, 49-58.
33. Bjorklund, A., Stenevi, U., Dunnett, S.B., Iversen, S.D. (1981) Functional reactivation of the deafferented neostriatum by nigral transplants. Nature, 289, 497-499.
34. Bjorklund, A., Stenevi, U., Schmidt, R.H., Dunnett, S.B., Gage, F.H. (1983) Intracerebral grafting of neuronal cell suspensions. I. Introduction and general methods of preparation. Acta Physiol. Scand. Suppl., 522, 1-7.
35. Bjorklund, A., Stenevi, U., Schmidt, R.H., Dunnett, S.B., Gage, F.H. (1983) Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cell suspensions implanted in different brain sites. Acta Physiol. Scand. Suppl., 522, 9-18.
36. Bjorklund, A., Stenevi, U., Svendgaard, N. (1976) Growth of transplanted monoaminergic neurones into the adult hippocampus along the perforant path. Nature, 262, 787-790.
37. Bjorklund, L.M., Sanchez-Pernaute, R., Chung, S., Andersson, T., Chen, I.Y., McNaught, K.S., Brownell, A.L., Jenkins, B.G., Wahlestedt, C., Kim, K.S., Isacson, O. (2002) Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. USA, 99, 2344-2349.
38. Blackinton, J., Ahmad, R., Miller, D.W., van der Brug, M.P., Canet-Aviles, R.M., Hague, S.M., Kaleem, M., Cookson, M.R. (2005) Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular localization. Brain Res. Mol. Brain Res., 134, 76-83.
39. Blanc, E.M., Keller, J.N., Fernandez, S., Mattson, M.P. (1998) 4-hydroxynonenal, a lipid peroxidation product, impairs glutamate transport in cortical astrocytes. Glia, 22, 149-160.
40. Blanchard-Fillion, B., Souza, J.M., Friel, T., Jiang, G.C., Vrana, K., Sharov, V., Barron, L., Schoneich, C., Quijano, C., Alvarez, B., Radi, R., Przedborski, S., Fernando, G.S., Horwitz, J., Ischiropoulos, H. (2001) Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J. Biol. Chem., 276, 46017-46023.
41. Blum, D., Torch, S., Nissou, M.F., Verna, J.M. (2001) 6-hydroxydopamine-induced nuclear factor-kappa B activation in PC12 cells. Biochem. Pharmacol., 62, 473-481.
42. Bogerts, B. (1981) A brainstem atlas of catecholaminergic neurons in man, using melanin as a natural marker. J. Comp. Neurol., 197, 63-80.
43. Bondy, S.C., Ali, S.F., Guo-Ross, S. (1998) Aluminum but not iron treatment induces pro-oxidant events in the rat brain. Mol. Chem. Neuropathol., 34, 219-232.
44. Bonifati, V., Rizzu, P., Squitieri, F., Krieger, E., Vanacore, N., van Swieten, J.C., Brice, A., van Duijn, C.M., Oostra, B., Meco, G., Heutink, P. (2003) DJ-1 (PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol. Sci., 24, 159-160.
45. Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 24, 197-211.
46. Bresolin, N., Bet, L., Binda, A., Moggio, M., Comi, G., Nador, F., Ferrante, C., Carenzi, A., Scarlato, G. (1988) Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology, 38, 892-899.
47. Bresolin, N., Bet, L., Ferrante, C., Binda, A., Carenzi, A., Moggio, M., Comi, G., Scarlato, G. (1988) Immunological and biochemical studies and pilot therapeutic trial with ubidecarenone in Kearns-Sayre patients. Adv. Neurol., 48, 239-256.
48. Burke, R.E., Antonelli, M., Sulzer, D. (1998) Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J. Neurochem., 71, 517-525.
49. Bush, A.I., Masters, C.L., Tanzi, R.E. (2003) Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. Proc. Natl. Acad. Sci. USA, 100, 11193-11194.
50. Cabin, D.E., Shimazu, K., Murphy, D., Cole, N.B., Gottschalk, W., McIlwain, K.L., Orrison, B., Chen, A., Ellis, C.E., Paylor, R., Lu, B., Nussbaum, R.L. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci., 22, 8797-8807.
51. Campbell, A., Yang, E.Y., Tsai-Turton, M., Bondy, S.C. (2002) Pro-inflammatory effects of aluminum in human glioblastoma cells. Brain Res., 933, 60-65.
52. Cao, G., Sofic, E., Prior, R.L. (1997) Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radic. Biol. Med., 22, 749-760.
53. Cappai, R., Leck, S.L., Tew, D.J., Williamson, N.A., Smith, D.P., Galatis, D., Sharples, R.A., Curtain, C.C., Ali, F.E., Cherny, R.A., Culvenor, J.G., Bottomley, S.P., Masters, C.L., Barnham, K.J., Hill, A.F. (2005) Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J., 19, 1377-1379.
54. Carini, R., Bellomo, G., Paradisi, L., Dianzani, M.U., Albano, E. (1996) 4-Hydroxynonenal triggers Ca2+ influx in isolated rat hepatocytes. Biochem. Biophys. Res. Commun., 218, 772-776.
55. Carta, M., Lindgren, H.S., Lundblad, M., Stancampiano, R., Fadda, F., Cenci, M.A. (2006) Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem., 96, 1718-1727.
56. Caughman, S.W., Hentze, M.W., Rouault, T.A., Harford, J.B., Klausner, R.D. (1988) The iron-responsive element is the single element responsible for iron-dependent translational regulation of ferritin biosynthesis. Evidence for function as the binding site for a translational repressor. J. Biol. Chem., 263, 19048-19052.
57. Chan, P.L., Nutt, J.G., Holford, N.H. (2007) Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharm. Res., 24, 791-802.
58. Chartier-Harlin, M.C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., Waucquier, N., Defebvre, L., Amouyel, P., Farrer, M., Destee, A. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 364, 1167-1169.
59. Chen, Y.H., Harvey, B.K., Hoffman, A.F., Wang, Y., Chiang, Y.H., Lupica, C.R. (2007) MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. FASEB J., 22(1), 261-275.
60. Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., Barnham, K.J., Volitakis, I., Fraser, F.W., Kim, Y., Huang, X., Goldstein, L.E., Moir, R.D., Lim, J.T., Beyreuther, K., Zheng, H., Tanzi, R.E., Masters, C.L., Bush, A.I. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 30, 665-676.
61. Chiba-Falek, O., Lopez, G.J., Nussbaum, R.L. (2006) Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov. Disord., 21, 1703-1708.
62. Chinta, S.J., Andersen, J.K. (2008) Redox imbalance in Parkinson's disease. Biochim. Biophys. Acta, 1780(11), 1362-1367.
63. Chinta, S.J., Kumar, M.J., Hsu, M., Rajagopalan, S., Kaur, D., Rane, A., Nicholls, D.G., Choi, J., Andersen, J.K. (2007) Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J. Neurosci., 27, 13997-14006.
64. Chiueh, C.C., Wu, R.M., Mohanakumar, K.P., Sternberger, L.M., Krishna, G., Obata, T., Murphy, D.L. (1994) In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann. N. Y. Acad. Sci., 738, 25-36.
65. Clarkson, E.D., Edwards-Prasad, J., Freed, C.R., Prasad, K.N. (1999) Immortalized dopamine neurons: A model to study neurotoxicity and neuroprotection. Proc. Soc. Exp. Biol. Med., 222, 157-163.
66. Cleren, C., Yang, L., Lorenzo, B., Calingasan, N.Y., Schomer, A., Sireci, A., Wille, E.J., Beal, M.F. (2008) Therapeutic effects of co-enzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J. Neurochem., 104, 1613-1621.
67. Cohen, G. (1987) Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv. Neurol., 45, 119-125.
68. Cohen, G. (1990) Monoamine oxidase and oxidative stress at dopaminergic synapses. J. Neural. Transm. Suppl., 32, 229-238.
69. Colosimo, C., Merello, M., Hughes, A.J., Sieradzan, K., Lees, A.J. (1996) Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J. Neurol. Neurosurg. Psychiatry, 60, 634-637.
70. Connor, B., Kozlowski, D.A., Unnerstall, J.R., Elsworth, J.D., Tillerson, J.L., Schallert, T., Bohn, M.C. (2001) Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. Exp. Neurol., 169, 83-95.
71. Connor, J.R., Menzies, S.L., St Martin, S.M., Mufson, E.J. (1990) Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res., 27, 595-611.
72. Conway, K.A., Harper, J.D., Lansbury, P.T., Jr. (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry, 39, 2552-2563.
73. Conway, K.A., Rochet, J.C., Bieganski, R.M., Lansbury, P.T., Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science, 294, 1346-1349.
74. Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., Liu, K., Xu, K., Strathearn, K.E., Liu, F., Cao, S., Caldwell, K.A., Caldwell, G.A., Marsischky, G., Kolodner, R.D., Labaer, J., Rochet, J.C., Bonini, N.M., Lindquist, S. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science, 313, 324-328.
75. Corasaniti, M.T., Strongoli, M.C., Pisanelli, A., Bruno, P., Rotiroti, D., Nappi, G., Nistico, G. (1992) Distribution of paraquat into the brain after its systemic injection in rats. Funct. Neurol., 7, 51-56.
76. Crompton, D.E., Chinnery, P.F., Fey, C., Curtis, A.R., Morris, C.M., Kierstan, J., Burt, A., Young, F., Coulthard, A., Curtis, A., Ince, P.G., Bates, D., Jackson, M.J., Burn, J. (2002) Neuroferritinopathy: a window on the role of iron in neurodegeneration. Blood Cells Mol. Dis., 29, 522-531.
77. Cubells, J.F., Rayport, S., Rajendran, G., Sulzer, D. (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci., 14, 2260-2271.
78. Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., Sulzer, D. (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science, 305, 1292-1295.
79. Dallman, P.R., Spirito, R.A. (1977) Brain iron in the rat: extremely slow turnover in normal rats may explain long-lasting effects of early iron deficiency. J. Nutr., 107, 1075-1081.
80. Davidson, W.S., Jonas, A., Clayton, D.F., George, J.M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem., 273, 9443-9449.
81. De Bie, R.M., Schuurman, P.R., Esselink, R.A., Bosch, D.A., Speelman, J.D. (2002) Bilateral pallidotomy in Parkinson's disease: a retrospective study. Mov. Disord., 17, 533-538.
82. de la Fuente-Fernandez, R., Schulzer, M., Stoessl, A.J. (2004) Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol. Psychiatry, 56, 67-71.
83. de Rijk, M.C., Breteler, M.M., den Breeijen, J.H., Launer, L.J., Grobbee, D.E., van der Meche, F.G., Hofman, A. (1997) Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch. Neurol., 54, 762-765.
84. Deinard, A.S., List, A., Lindgren, B., Hunt, J.V., Chang, P.N. (1986) Cognitive deficits in iron-deficient and iron-deficient anemic children. J. Pediatr., 108, 681-689.
85. Deng, H., Le, W., Guo, Y., Hunter, C.B., Xie, W., Huang, M., Jankovic, J. (2006) Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J. Neurol. Sci., 251, 102-106.
86. Deng, J., Lewis, P.A., Greggio, E., Sluch, E., Beilina, A., Cookson, M.R. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl. Acad. Sci. USA, 105, 1499-1504.
87. Desole, M.S., Esposito, G., Migheli, R., Sircana, S., Delogu, M.R., Fresu, L., Miele, M., de Natale, G., Miele, E. (1997) Glutathione deficiency potentiates manganese toxicity in rat striatum and brain-stem and in PC12 cells. Pharmacol. Res., 36, 285-292.
88. Desole, M.S., Sciola, L., Delogu, M.R., Sircana, S., Migheli, R., Miele, E. (1997) Role of oxidative stress in the manganese and 1-methyl-4-(2′-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced apoptosis in PC12 cells. Neurochem. Int., 31, 169-176.
89. Devasagayam, T.P., Werner, T., Ippendorf, H., Martin, H.D., Sies, H. (1992) Synthetic carotenoids, novel polyene polyketones and new capsorubin isomers as efficient quenchers of singlet molecular oxygen. Photochem. Photobiol., 55, 511-514.
90. Dexter, D.T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F.R., Daniel, S.E., Lees, A.J., Jenner, P., Marsden, C.D. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain, 114 (Pt 4), 1953-1975.
91. Dexter, D.T., Carayon, A., Vidailhet, M., Ruberg, M., Agid, F., Agid, Y., Lees, A.J., Wells, F.R., Jenner, P., Marsden, C.D. (1990) Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem., 55, 16-20.
92. Dexter, D.T., Wells, F.R., Lees, A.J., Agid, F., Agid, Y., Jenner, P., Marsden, C.D. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem., 52, 1830-1836.
93. Dhopesh, V.P., Yagnik, P.M., Weddington, W.W. (1997) Can cocaine abuse cause parkinsonism? Am. J. Addict., 6, 177-179.
94. Di Mascio, P., Devasagayam, T.P., Kaiser, S., Sies, H. (1990) Carotenoids, tocopherols and thiols as biological singlet molecular oxygen quenchers. Biochem. Soc. Trans., 18, 1054-1056.
95. Di Stasi, A.M., Mallozzi, C., Macchia, G., Petrucci, T.C., Minetti, M. (1999) Peroxynitrite induces tryosine nitration and modulates tyrosine phosphorylation of synaptic proteins. J. Neurochem., 73, 727-735.
96. Dietrich, J.B., Mangeol, A., Revel, M.O., Burgun, C., Aunis, D., Zwiller, J. (2005) Acute or repeated cocaine administration generates reactive oxygen species and induces antioxidant enzyme activity in dopaminergic rat brain structures. Neuropharmacology, 48, 965-974.
97. Ding, W.Q., Liu, B., Vaught, J.L., Palmiter, R.D., Lind, S.E. (2006) Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol. Cancer Ther., 5, 1864-1872.
98. Ding, W.Q., Liu, B., Vaught, J.L., Yamauchi, H., Lind, S.E. (2005) Anticancer activity of the antibiotic clioquinol. Cancer Res., 65, 3389-3395.
99. Ding, Y.M., Jaumotte, J.D., Signore, A.P., Zigmond, M.J. (2004) Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J. Neurochem., 89, 776-787.
100. Doraiswamy, P.M., Finefrock, A.E. (2004) Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol., 3, 431-434.
101. Dostrovsky, J.O., Levy, R., Wu, J.P., Hutchison, W.D., Tasker, R.R., Lozano, A.M. (2000) Microstimulation-induced inhibition of neuronal firing in human globus pallidus. J. Neurophysiol., 84, 570-574.
102. Double, K.L. (2006) Functional effects of neuromelanin and synthetic melanin in model systems. J. Neural. Transm., 113, 751-756.
103. Double, K.L., Ben-Shachar, D., Youdim, M.B., Zecca, L., Riederer, P., Gerlach, M. (2002) Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol. Teratol., 24, 621-628.
104. Double, K.L., Gerlach, M., Youdim, M.B., Riederer, P. (2000) Impaired iron homeostasis in Parkinson's disease. J. Neural. Transm. Suppl., 37-58.
105. Du, B., Wu, P., Boldt-Houle, D.M., Terwilliger, E.F. (1996) Efficient transduction of human neurons with an adeno-associated virus vector. Gene Ther., 3, 254-261.
106. Dunnett, S.B., Bjorklund, A., Schmidt, R.H., Stenevi, U., Iversen, S.D. (1983) Intracerebral grafting of neuronal cell suspensions. V. Behavioural recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions. Acta Physiol. Scand. Suppl., 522, 39-47.
107. Emerit, I., Keck, M., Levy, A., Feingold, J., Michelson, A.M. (1982) Activated oxygen species at the origin of chromosome breakage and sister-chromatid exchanges. Mutat. Res., 103, 165-172.
108. Emson, P.C., Bjorklund, A., Stenevi, U. (1976) Possible regeneration of gamma-aminobutyric acid-containing fibres into irides transplanted into the central nervous system. Nature, 259, 567-570.
109. Erola, T., Heikkinen, E.R., Haapaniemi, T., Tuominen, J., Juolasmaa, A., Myllyla, V.V. (2006) Efficacy of bilateral subthalamic nucleus (STN) stimulation in Parkinson's disease. Acta Neurochir. (Wien), 148, 389-394.
110. Fahn, S. (2006) A new look at levodopa based on the ELLDOPA study. J. Neural. Transm. Suppl., 419-426.
111. Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C.W., Tanner, C., Marek, K. (2004) Levodopa and the progression of Parkinson's disease. N. Engl. J. Med., 351, 2498-2508.
112. Faucheux, B.A., Martin, M.E., Beaumont, C., Hunot, S., Hauw, J.J., Agid, Y., Hirsch, E.C. (2002) Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem., 83, 320-330.
113. Feigin, A., Kaplitt, M.G., Tang, C., Lin, T., Mattis, P., Dhawan, V., During, M.J., Eidelberg, D. (2007) Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. USA, 104, 19559-19564.
114. Finkelstein, D.I., Stanic, D., Parish, C.L., Tomas, D., Dickson, K., Horne, M.K. (2000) Axonal sprouting following lesions of the rat substantia nigra. Neuroscience, 97, 99-112.
115. Flaten, T.P. (2001) Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water. Brain Res. Bull., 55, 187-196.
116. Fornai, F., Lenzi, P., Ferrucci, M., Lazzeri, G., di Poggio, A.B., Natale, G., Busceti, C.L., Biagioni, F., Giusiani, M., Ruggieri, S., Paparelli, A. (2005) Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res. Bull., 65, 405-413.
117. Fornai, F., Lenzi, P., Gesi, M., Ferrucci, M., Lazzeri, G., Capobianco, L., de Blasi, A., Battaglia, G., Nicoletti, F., Ruggieri, S., Paparelli, A. (2004) Similarities between methamphetamine toxicity and proteasome inhibition. Ann. N. Y. Acad. Sci., 1025, 162-170.
118. Fornai, F., Schluter, O.M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C.L., Pontarelli, F., Battaglia, G., Pellegrini, A., Nicoletti, F., Ruggieri, S., Paparelli, A., Sudhof, T.C. (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. USA, 102, 3413-3418.
119. Fornstedt, B. (1990) Role of catechol autooxidation in the degeneration of dopamine neurons. Acta Neurol. Scand. Suppl., 129, 12-14.
120. Forsmark-Andree, P., Lee, C.P., Dallner, G., Ernster, L. (1997) Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. Free Radic. Biol. Med., 22, 391-400.
121. Fortin, D.L., Nemani, V.M., Voglmaier, S.M., Anthony, M.D., Ryan, T.A., Edwards, R.H. (2005) Neural activity controls the synaptic accumulation of alpha-synuclein. J. Neurosci., 25, 10913-10921.
122. Fortin, D.L., Troyer, M.D., Nakamura, K., Kubo, S., Anthony, M.D., Edwards, R.H. (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci., 24, 6715-6723.
123. Fountaine, T.M., Wade-Martins, R. (2007) RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J. Neurosci. Res., 85, 351-363.
124. Fredriksson, A., Archer, T. (2007) Postnatal iron overload destroys NA-DA functional interactions. J. Neural. Transm., 114, 195-203.
125. Fredriksson, A., Schroder, N., Eriksson, P., Izquierdo, I., Archer, T. (2001) Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkinsonism Relat. Disord., 7, 97-105.
126. Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J.Q., Eidelberg, D., Fahn, S. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med., 344, 710-719.
127. Freed, C.R., Leehey, M.A., Zawada, M., Bjugstad, K., Thompson, L., Breeze, R.E. (2003) Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? J. Neurol., 250(Suppl 3), III44-46.
128. Freed, W.J. (2004) A perspective on transplantation therapy and stem cells for Parkinson's disease. Cell Transplant., 13, 319-327.
129. Friedlich, A.L., Tanzi, R.E., Rogers, J.T. (2007) The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol. Psychiatry, 12, 222-223.
130. Fujimura, M., Morita-Fujimura, Y., Kawase, M., Copin, J.C., Calagui, B., Epstein, C.J., Chan, P.H. (1999) Manganese superoxide dismutase mediates the early release of mitochondrial cytochrome C and subsequent DNA fragmentation after permanent focal cerebral ischemia in mice. J. Neurosci., 19, 3414-3422.
131. Fulceri, F., Biagioni, F., Lenzi, P., Falleni, A., Gesi, M., Ruggieri, S., Fornai, F. (2006) Nigrostriatal damage with 6-OHDA: validation of routinely applied procedures. Ann. N. Y. Acad. Sci., 1074, 344-348.
132. Fung, H.C., Scholz, S., Matarin, M., Simon-Sanchez, J., Hernandez, D., Britton, A., Gibbs, J.R., Langefeld, C., Stiegert, M.L., Schymick, J., Okun, M.S., Mandel, R.J., Fernandez, H.H., Foote, K.D., Rodriguez, R.L., Peckham, E., De Vrieze, F.W., Gwinn-Hardy, K., Hardy, J.A., Singleton, A. (2006) Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol., 5, 911-916.
133. Gage, F.H., Bjorklund, A., Stenevi, U., Dunnett, S.B. (1983) Intracerebral grafting of neuronal cell suspensions. VIII. Survival and growth of implants of nigral and septal cell suspensions in intact brains of aged rats. Acta Physiol. Scand. Suppl., 522, 67-75.
134. Gal, S., Fridkin, M., Amit, T., Zheng, H., Youdim, M.B. (2006) M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J. Neural. Transm. Suppl., 447-456.
135. Gal, S., Zheng, H., Fridkin, M., Youdim, M.B. (2005) Novel multi-functional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem., 95, 79-88.
136. Gao, X., Chen, H., Fung, T.T., Logroscino, G., Schwarzschild, M.A., Hu, F.B., Ascherio, A. (2007) Prospective study of dietary pattern and risk of Parkinson disease. Am. J. Clin. Nutr., 86, 1486-1494.
137. Garruto, R.M., Fukatsu, R., Yanagihara, R., Gajdusek, D.C., Hook, G., Fiori, C.E. (1984) Imaging of calcium and aluminum in neurofibrillary tangle-bearing neurons in parkinsonism-dementia of Guam. Proc. Natl. Acad. Sci. USA, 81, 1875-1879.
138. Gauthier, E., Fortier, I., Courchesne, F., Pepin, P., Mortimer, J., Gauvreau, D. (2000) Aluminum forms in drinking water and risk of Alzheimer's disease. Environ. Res., 84, 234-246.
139. Giasson, B.I., Duda, J.E., Murray, I.V., Chen, Q., Souza, J.M., Hurtig, H.I., Ischiropoulos, H., Trojanowski, J.Q., Lee, V.M. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science, 290, 985-989.
140. Gil, B., Sanz, M.J., Terencio, M.C., Ferrandiz, M.L., Bustos, G., Paya, M., Gunasegaran, R., Alcaraz, M.J. (1994) Effects of flavonoids on Naja naja and human recombinant synovial phospholipases A2 and inflammatory responses in mice. Life Sci., 54, PL333-338.
141. Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N., Heywood, P. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 9, 589-595.
142. Giulivi, C., Davies, K.J. (1993) Dityrosine and tyrosine oxidation products are endogenous markers for the selective proteolysis of oxidatively modified red blood cell hemoglobin by (the 19 S) proteasome. J. Biol. Chem., 268, 8752-8759.
143. Goedert, M. (1997) Familial Parkinson's disease. The awakening of alpha-synuclein. Nature, 388, 232-233.
144. Golbe, L.I., Farrell, T.M., Davis, P.H. (1988) Case-control study of early life dietary factors in Parkinson's disease. Arch. Neurol., 45, 1350-1353.
145. Goldberg, M.S., Fleming, S.M., Palacino, J.J., Cepeda, C., Lam, H.A., Bhatnagar, A., Meloni, E.G., Wu, N., Ackerson, L.C., Klapstein, G.J., Gajendiran, M., Roth, B.L., Chesselet, M.F., Maidment, N.T., Levine, M.S., Shen, J. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem., 278, 43628-43635.
146. Goldstein, L.E., Leopold, M.C., Huang, X., Atwood, C.S., Saunders, A.J., Hartshorn, M., Lim, J.T., Faget, K.Y., Muffat, J.A., Scarpa, R.C., Chylack, L.T., Jr., Bowden, E.F., Tanzi, R.E., Bush, A.I. (2000) 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin crosslinking by metal ion reduction. Biochemistry, 39, 7266-7275.
147. Golub, M.S., Germann, S.L., Araiza, R.S., Reader, J.R., Griffey, S.M., Lloyd, K.C. (2005) Movement disorders in the Hfe knockout mouse. Nutr. Neurosci., 8, 239-244.
148. Golub, M.S., Hogrefe, C.E., Germann, S.L. (2007) Iron deprivation during
149. Gomez-Vargas, M., Nishibayashi-Asanuma, S., Asanuma, M., Kondo, Y., Iwata, E., Ogawa, N. (1998) Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res., 790, 202-208.
150. Gong, L., Daigneault, E.A., Acuff, R.V., Kostrzewa, R.M. (1991) Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity. Neuroreport, 2, 544-546.
151. Good, P.F., Olanow, C.W., Perl, D.P. (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res., 593, 343-346.
152. Goodwill, K.E., Sabatier, C., Marks, C., Raag, R., Fitzpatrick, P.F., Stevens, R.C. (1997) Crystal structure of tyrosine hydroxylase at 2.3 A and its implications for inherited neurodegenerative diseases. Nat. Struct. Biol., 4, 578-585.
153. Goodwill, K.E., Sabatier, C., Stevens, R.C. (1998) Crystal structure of tyrosine hydroxylase with bound cofactor analogue and iron at 2.3 A resolution: self-hydroxylation of Phe300 and the pterin-binding site. Biochemistry, 37, 13437-13445.
154. Gotz, M.E., Double, K., Gerlach, M., Youdim, M.B., Riederer, P. (2004) The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci., 1012, 193-208.
155. Graves, A.B., Rosner, D., Echeverria, D., Mortimer, J.A., Larson, E.B. (1998) Occupational exposures to solvents and aluminium and estimated risk of Alzheimer's disease. Occup. Environ. Med., 55, 627-633.
156. Greenbaum, E.A., Graves, C.L., Mishizen-Eberz, A.J., Lupoli, M.A., Lynch, D.R., Englander, S.W., Axelsen, P.H., Giasson, B.I. (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem., 280, 7800-7807.
157. Griffiths, P.D., Dobson, B.R., Jones, G.R., Clarke, D.T. (1999) Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain, 122 (Pt 4), 667-673.
158. Grundemann, J., Schlaudraff, F., Haeckel, O., Liss, B. (2008) Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res., 36, e38.
159. Gutteridge, J.M., Quinlan, G.J., Clark, I., Halliwell, B. (1985) Aluminium salts accelerate peroxidation of membrane lipids stimulated by iron salts. Biochim. Biophys. Acta, 835, 441-447.
160. Haberler, C., Alesch, F., Mazal, P.R., Pilz, P., Jellinger, K., Pinter, M.M., Hainfellner, J.A., Budka, H. (2000) No tissue damage by chronic deep brain stimulation in Parkinson's disease. Ann. Neurol., 48, 372-376.
161. Hachinski, V. (1998) Aluminum exposure and risk of Alzheimer disease. Arch. Neurol., 55, 742.
162. Hallett, M., Litvan, I. (1999) Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease. Neurology, 53, 1910-1921.
163. Hallett, M., Litvan, I. (2000) Scientific position paper of the Movement Disorder Society evaluation of surgery for Parkinson's disease. Task Force on Surgery for Parkinson's Disease of the American Academy of Neurology Therapeutic and Technology Assessment Committee. Mov. Disord., 15, 436-438.
164. Halliwell, B. (2006) Oxidative stress and neurodegeneration: where are we now? J. Neurochem., 97, 1634-1658.
165. Hanasaki, Y., Ogawa, S., Fukui, S. (1994) The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radic. Biol. Med., 16, 845-850.
166. Hanrott, K., Gudmunsen, L., O'Neill, M.J., Wonnacott, S. (2006) 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem., 281, 5373-5382.
167. Hansen, T.M., Nielsen, H., Bernth, N., Moos, T. (1999) Expression of ferritin protein and subunit mRNAs in normal and iron deficient rat brain. Brain Res. Mol. Brain Res., 65, 186-197.
168. Hatano, Y., Li, Y., Sato, K., Asakawa, S., Yamamura, Y., Tomiyama, H., Yoshino, H., Asahina, M., Kobayashi, S., Hassin-Baer, S., Lu, C.S., Ng, A.R., Rosales, R.L., Shimizu, N., Toda, T., Mizuno, Y., Hattori, N. (2004) Novel PINK1 mutations in early-onset parkinsonism. Ann. Neurol., 56, 424-427.
169. Hattori, N., Kitada, T., Matsumine, H., Asakawa, S., Yamamura, Y., Yoshino, H., Kobayashi, T., Yokochi, M., Wang, M., Yoritaka, A., Kondo, T., Kuzuhara, S., Nakamura, S., Shimizu, N., Mizuno, Y. (1998) Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann. Neurol., 44, 935-941.
170. Hayashi, S., Wakabayashi, K., Ishikawa, A., Nagai, H., Saito, M., Maruyama, M., Takahashi, T., Ozawa, T., Tsuji, S., Takahashi, H. (2000) An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov. Disord., 15, 884-888.
171. Hayashita-Kinoh, H., Yamada, M., Yokota, T., Mizuno, Y., Mochizuki, H. (2006) Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem. Biophys. Res. Commun., 341, 1088-1095.
172. Hellenbrand, W., Boeing, H., Robra, B.P., Seidler, A., Vieregge, P., Nischan, P., Joerg, J., Oertel, W.H., Schneider, E., Ulm, G. (1996) Diet and Parkinson's disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology, 47, 644-650.
173. Hellenbrand, W., Seidler, A., Boeing, H., Robra, B.P., Vieregge, P., Nischan, P., Joerg, J., Oertel, W.H., Schneider, E., Ulm, G. (1996) Diet and Parkinson's disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology, 47, 636-643.
174. Henderson, J., Doherty, K., Allbutt, H., Billing, R. (2006) Effects of pallidotomy on motor symptoms in an animal model of Parkinson's disease. Behav. Brain Res., 169, 29-38.
175. Henderson, J.M., Carpenter, K., Cartwright, H., Halliday, G.M. (2000) Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann. Neurol., 47, 345-352.
176. Henderson, J.M., Stanic, D., Tomas, D., Patch, J., Horne, M.K., Bourke, D., Finkelstein, D.I. (2005) Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys. Behav. Brain Res., 160, 267-276.
177. Hermida-Ameijeiras, A., Mendez-Alvarez, E., Sanchez-Iglesias, S., Sanmartin-Suarez, C., Soto-Otero, R. (2004) Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem. Int., 45, 103-116.
178. Hershko, C., Avramovici-Grisaru, S., Link, G., Gelfand, L., Sarel, S. (1981) Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J. Lab. Clin. Med., 98, 99-108.
179. Hilker, R., Portman, A.T., Voges, J., Staal, M.J., Burghaus, L., van Laar, T., Koulousakis, A., Maguire, R.P., Pruim, J., de Jong, B.M., Herholz, K., Sturm, V., Heiss, W.D., Leenders, K.L. (2005) Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J. Neurol. Neurosurg. Psychiatry, 76, 1217-1221.
180. Hirsch, E.C., Brandel, J.P., Galle, P., Javoy-Agid, F., Agid, Y. (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem., 56, 446-451.
181. Hod, Y., Pentyala, S.N., Whyard, T.C., El-Maghrabi, M.R. (1999) Identification and characterization of a novel protein that regulates RNA-protein interaction. J. Cell Biochem., 72, 435-444.
182. Hoglinger, G.U., Feger, J., Prigent, A., Michel, P.P., Parain, K., Champy, P., Ruberg, M., Oertel, W.H., Hirsch, E.C. (2003) Chronic systemic complex I inhibition induces a hypokinetic multi-system degeneration in rats. J. Neurochem., 84, 491-502.
183. Holford, N.H., Chan, P.L., Nutt, J.G., Kieburtz, K., Shoulson, I. (2006) Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J. Pharmacokinet. Pharmacodyn., 33, 281-311.
184. Hornykiewicz, O., Kish, S.J. (1987) Biochemical pathophysiology of Parkinson's disease. Adv. Neurol., 45, 19-34.
185. Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J.P., Lees, A., Oertel, W., Poewe, W., Rascol, O., Sampaio, C. (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur. J. Neurol., 13, 1186-1202.
186. Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J.P., Lees, A., Oertel, W., Poewe, W., Rascol, O., Sampaio, C. (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur. J. Neurol., 13, 1170-1185.
187. Huang, C.C., Chu, N.S., Lu, C.S., Chen, R.S., Calne, D.B. (1998) Long-term progression in chronic manganism: ten years of follow-up. Neurology, 50, 698-700.
188. Huang, C.C., Chu, N.S., Lu, C.S., Chen, R.S., Schulzer, M., Calne, D.B. (2007) The natural history of neurological manganism over 18 years. Parkinsonism Relat. Disord., 13, 143-145.
189. Huang, C.C., Lu, C.S., Chu, N.S., Hochberg, F., Lilienfeld, D., Olanow, W., Calne, D.B. (1993) Progression after chronic manganese exposure. Neurology, 43, 1479-1483.
190. Hulet, S.W., Heyliger, S.O., Powers, S., Connor, J.R. (2000) Oligodendrocyte progenitor cells internalize ferritin via clathrin-dependent receptor mediated endocytosis. J. Neurosci. Res., 61, 52-60.
191. Hutchinson, M., Gurney, S., Newson, R. (2007) GDNF in Parkinson disease: an object lesson in the tyranny of type II. J. Neurosci. Methods, 163, 190-192.
192. Hyun, D.H., Lee, M., Halliwell, B., Jenner, P. (2005) Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults. J. Neurosci. Res., 82, 232-244.
193. Iacovelli, L., Fulceri, F., De Blasi, A., Nicoletti, F., Ruggieri, S., Fornai, F. (2006) The neurotoxicity of amphetamines: bridging drugs of abuse and neurodegenerative disorders. Exp. Neurol., 201, 24-31.
194. Iancu, R., Mohapel, P., Brundin, P., Paul, G. (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav. Brain Res., 162, 1-10.
195. Ibanez, P., Bonnet, A.M., Debarges, B., Lohmann, E., Tison, F., Pollak, P., Agid, Y., Durr, A., Brice, A. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet, 364, 1169-1171.
196. Inden, M., Taira, T., Kitamura, Y., Yanagida, T., Tsuchiya, D., Takata, K., Yanagisawa, D., Nishimura, K., Taniguchi, T., Kiso, Y., Yoshimoto, K., Agatsuma, T., Koide-Yoshida, S., Iguchi-Ariga, S.M., Shimohama, S., Ariga, H. (2006) PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol. Dis., 24, 144-158.
197. Irizarry, M.C., Growdon, W., Gomez-Isla, T., Newell, K., George, J.M., Clayton, D.F., Hyman, B.T. (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol., 57, 334-337.
198. Jakes, R., Spillantini, M.G., Goedert, M. (1994) Identification of two distinct synucleins from human brain. FEBS Lett., 345, 27-32.
199. Jakowec, M.W., Petzinger, G.M. (2004) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates. Comp. Med., 54, 497-513.
200. Jenner, P., Olanow, C.W. (2006) The pathogenesis of cell death in Parkinson's disease. Neurology, 66, S24-36.
201. Johnson, C.C., Gorell, J.M., Rybicki, B.A., Sanders, K., Peterson, E.L. (1999) Adult nutrient intake as a risk factor for Parkinson's disease. Int. J. Epidemiol., 28, 1102-1109.
202. Jonsson, G., Sachs, C. (1975) Actions of 6-hydroxydopamine quinones on catecholamine neurons. J. Neurochem., 25, 509-516.
203. Junn, E., Mouradian, M.M. (2002) Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett., 320, 146-150.
204. Kahle, P.J., Neumann, M., Ozmen, L., Muller, V., Odoy, S., Okamoto, N., Jacobsen, H., Iwatsubo, T., Trojanowski, J.Q., Takahashi, H., Wakabayashi, K., Bogdanovic, N., Riederer, P., Kretzschmar, H.A., Haass, C. (2001) Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am. J. Pathol., 159, 2215-2225.
205. Kaur, D., Peng, J., Chinta, S.J., Rajagopalan, S., Di Monte, D.A., Cherny, R.A., Andersen, J.K. (2006) Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol. Aging, 28(6), 907-913.
206. Kaur, D., Rajagopalan, S., Chinta, S., Kumar, J., Di Monte, D., Cherny, R.A., Andersen, J.K. (2007) Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration. Brain Res., 1140, 188-194.
207. Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J.Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M.F., Di-Monte, D., Volitaskis, I., Ellerby, L., Cherny, R.A., Bush, A.I., Andersen, J.K. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron, 37, 899-909.
208. Keller, J.N., Hanni, K.B., Markesbery, W.R. (2000) Impaired proteasome function in Alzheimer's disease. J. Neurochem., 75, 436-439.
209. Keyer, K., Imlay, J.A. (1996) Superoxide accelerates DNA damage by elevating free-iron levels. Proc. Natl. Acad. Sci. USA, 93, 13635-13640.
210. Keyer, K., Imlay, J.A. (1997) Inactivation of dehydratase [4Fe-4S] clusters and disruption of iron homeostasis upon cell exposure to peroxynitrite. J. Biol. Chem., 272, 27652-27659.
211. Kihira, T., Yoshida, S., Yase, Y., Ono, S., Kondo, T. (2002) Chronic low-Ca/Mg high-Al diet induces neuronal loss. Neuropathology, 22, 171-179.
212. Kikinis, Z., Eisenstein, R.S., Bettany, A.J., Munro, H.N. (1995) Role of RNA secondary structure of the iron-responsive element in translational regulation of ferritin synthesis. Nucleic Acids Res., 23, 4190-4195.
213. Kim, R.H., Smith, P.D., Aleyasin, H., Hayley, S., Mount, M.P., Pownall, S., Wakeham, A., You-Ten, A.J., Kalia, S.K., Horne, P., Westaway, D., Lozano, A.M., Anisman, H., Park, D.S., Mak, T.W. (2005) Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. USA, 102, 5215-5220.
214. Kish, S.J., Shannak, K., Hornykiewicz, O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med., 318, 876-880.
215. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., Shimizu, N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608.
216. Klatzo, I., Wisniewski, H., Streicher, E. (1965) Experimental production of neurofibrillary degeneration. I. Light microscopic observations. J. Neuropathol. Exp. Neurol., 24, 187-199.
217. Kleiner-Fisman, G., Fisman, D.N., Sime, E., Saint-Cyr, J.A., Lozano, A.M., Lang, A.E. (2003) Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J. Neurosurg., 99, 489-495.
218. Klivenyi, P., Andreassen, O.A., Ferrante, R.J., Dedeoglu, A., Mueller, G., Lancelot, E., Bogdanov, M., Andersen, J.K., Jiang, D., Beal, M.F. (2000) Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J. Neurosci., 20, 1-7.
219. Koeppen, A.H. (1995) The history of iron in the brain. J. Neurol. Sci., 134(Suppl), 1-9.
220. Kogan, F.J., Nichols, W.K., Gibb, J.W. (1976) Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol., 36, 363-371.
221. Kondo, T., Ito, T., Sugita, Y. (1994) Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann. N. Y. Acad. Sci., 738, 222-229.
222. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., Brown, W.D., Holden, J.E., Pyzalski, R., Taylor, M.D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Deglon, N., Aebischer, P. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 290, 767-773.
223. Kordower, J.H., Palfi, S., Chen, E.Y., Ma, S.Y., Sendera, T., Cochran, E.J., Mufson, E.J., Penn, R., Goetz, C.G., Comella, C.D. (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol., 46, 419-424.
224. Kowall, N.W., Pendlebury, W.W., Kessler, J.B., Perl, D.P., Beal, M.F. (1989) Aluminum-induced neurofibrillary degeneration affects a subset of neurons in rabbit cerebral cortex, basal forebrain and upper brainstem. Neuroscience, 29, 329-337.
225. Kozlowski, D.A., Connor, B., Tillerson, J.L., Schallert, T., Bohn, M.C. (2000) Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp. Neurol., 166, 1-15.
226. Krack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P.D., Benazzouz, A., LeBas, J.F., Benabid, A.L., Pollak, P. (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med., 349, 1925-1934.
227. Kruger, R., Kuhn, W., Leenders, K.L., Sprengelmeyer, R., Muller, T., Woitalla, D., Portman, A.T., Maguire, R.P., Veenma, L., Schroder, U., Schols, L., Epplen, J.T., Riess, O., Przuntek, H. (2001) Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology, 56, 1355-1362.
228. Kubo, S., Nemani, V.M., Chalkley, R.J., Anthony, M.D., Hattori, N., Mizuno, Y., Edwards, R.H., Fortin, D.L. (2005) A combinatorial code for the interaction of alpha-synuclein with membranes. J. Biol. Chem., 280, 31664-31672.
229. Kurlan, R. (2005) "Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology, 64, 923-924.
230. Kuroda, Y., Mitsui, T., Kunishige, M., Matsumoto, T. (2006) Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells. Biochem. Biophys. Res. Commun., 348, 787-793.
231. Kuroda, Y., Mitsui, T., Kunishige, M., Shono, M., Akaike, M., Azuma, H., Matsumoto, T. (2006) Parkin enhances mitochondrial biogenesis in proliferating cells. Hum. Mol. Genet., 15, 883-895.
232. Lang, A.E., Gill, S., Patel, N.K., Lozano, A., Nutt, J.G., Penn, R., Brooks, D.J., Hotton, G., Moro, E., Heywood, P., Brodsky, M.A., Burchiel, K., Kelly, P., Dalvi, A., Scott, B., Stacy, M., Turner, D., Wooten, V.G., Elias, W.J., Laws, E.R., Dhawan, V., Stoessl, A.J., Matcham, J., Coffey, R.J., Traub, M. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol., 59, 459-466.
233. Langston, J.W., Ballard, P., Tetrud, J.W., Irwin, I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979-980.
234. Langston, J.W., Ballard, P.A., Jr. (1983) Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med., 309, 310.
235. Lavara-Culebras, E., Paricio, N. (2007) Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits. Gene, 400, 158-165.
236. LaVaute, T., Smith, S., Cooperman, S., Iwai, K., Land, W., Meyron-Holtz, E., Drake, S.K., Miller, G., Abu-Asab, M., Tsokos, M., Switzer, R., 3rd, Grinberg, A., Love, P., Tresser, N., Rouault, T.A. (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet, 27, 209-214.
237. Lee, C.S., Park, W.J., Ko, H.H., Han, E.S. (2006) Differential involvement of mitochondrial permeability transition in cytotoxicity of 1-methyl-4-phenylpyridinium and 6-hydroxydopamine. Mol. Cell Biochem., 289, 193-200.
238. Lee, J., Zhu, W.M., Stanic, D., Finkelstein, D.I., Horne, M.H., Henderson, J., Lawrence, A.J., O'Connor, L., Tomas, D., Drago, J., Horne, M.K. (2008) Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain, 131, 1574-1587.
239. Lee, M., Hyun, D., Halliwell, B., Jenner, P. (2001) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem., 76, 998-1009.
240. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M.J., Jonnalagada, S., Chernova, T., Dehejia, A., Lavedan, C., Gasser, T., Steinbach, P.J., Wilkinson, K.D., Polymeropoulos, M.H. (1998) The ubiquitin pathway in Parkinson's disease. Nature, 395, 451-452.
241. Leroy, E., Boyer, R., Polymeropoulos, M.H. (1998) Intron-exon structure of ubiquitin c-terminal hydrolase-L1. DNA Res., 5, 397-400.
242. LeVine, S.M. (1997) Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res., 760, 298-303.
243. Levites, Y., Weinreb, O., Maor, G., Youdim, M.B., Mandel, S. (2001) Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem., 78, 1073-1082.
244. Levites, Y., Youdim, M.B., Maor, G., Mandel, S. (2002) Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol., 63, 21-29.
245. Li, W., Lesuisse, C., Xu, Y., Troncoso, J.C., Price, D.L., Lee, M.K. (2004) Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J. Neurosci., 24, 7400-7409.
246. Liccione, J.J., Maines, M.D. (1988) Selective vulnerability of glutathione metabolism and cellular defense mechanisms in rat striatum to manganese. J. Pharmacol. Exp. Ther., 247, 156-161.
247. Lincoln, S., Vaughan, J., Wood, N., Baker, M., Adamson, J., Gwinn-Hardy, K., Lynch, T., Hardy, J., Farrer, M. (1999) Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport, 10, 427-429.
248. Ling, Z.D., Potter, E.D., Lipton, J.W., Carvey, P.M. (1998) Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp. Neurol., 149, 411-423.
249. Liu, S., Ninan, I., Antonova, I., Battaglia, F., Trinchese, F., Narasanna, A., Kolodilov, N., Dauer, W., Hawkins, R.D., Arancio, O. (2004) alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J., 23, 4506-4516.
250. Liu, Y., Fallon, L., Lashuel, H.A., Liu, Z., Lansbury, P.T., Jr. (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell, 111, 209-218.
251. Lo Bianco, C., Schneider, B.L., Bauer, M., Sajadi, A., Brice, A., Iwatsubo, T., Aebischer, P. (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 101, 17510-17515.
252. Logroscino, G., Marder, K., Cote, L., Tang, M.X., Shea, S., Mayeux, R. (1996) Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann. Neurol., 39, 89-94.
253. Logroscino, G., Marder, K., Graziano, J., Freyer, G., Slavkovich, V., Lojacono, N., Cote, L., Mayeux, R. (1998) Dietary iron, animal fats, and risk of Parkinson's disease. Mov. Disord., 13(Suppl 1), 13-16.
254. Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H.K., Brundin, P. (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem., 277, 38884-38894.
255. Lotharius, J., Brundin, P. (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci., 3, 932-942.
256. Lucking, C.B., Abbas, N., Durr, A., Bonifati, V., Bonnet, A.M., de Broucker, T., De Michele, G., Wood, N.W., Agid, Y., Brice, A. (1998) Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. Lancet, 352, 1355-1356.
257. MacMillan-Crow, L.A., Crow, J.P., Thompson, J.A. (1998) Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry, 37, 1613-1622.
258. Magaki, S., Mueller, C., Yellon, S.M., Fox, J., Kim, J., Snissarenko, E., Chin, V., Ghosh, M.C., Kirsch, W.M. (2007) Regional dissection and determination of loosely bound and non-heme iron in the developing mouse brain. Brain Res., 1158, 144-150.
259. Mann, V.M., Cooper, J.M., Daniel, S.E., Srai, K., Jenner, P., Marsden, C.D., Schapira, A.H. (1994) Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol., 36, 876-881.
260. Manning-Bog, A.B., McCormack, A.L., Li, J., Uversky, V.N., Fink, A.L., Di Monte, D.A. (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem., 277, 1641-1644.
261. Maraganore, D.M., Farrer, M.J., Hardy, J.A., Lincoln, S.J., McDonnell, S.K., Rocca, W.A. (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology, 53, 1858-1860.
262. Maraganore, D.M., Lesnick, T.G., Elbaz, A., Chartier-Harlin, M.C., Gasser, T., Kruger, R., Hattori, N., Mellick, G.D., Quattrone, A., Satoh, J., Toda, T., Wang, J., Ioannidis, J.P., de Andrade, M., Rocca, W.A. (2004) UCHL1 is a Parkinson's disease susceptibility gene. Ann. Neurol., 55, 512-521.
263. Marsden, C.D. (1961) Pigmentation in the nucleus substantiae nigrae of mammals. J. Anat., 95, 256-261.
264. Marsden, C.D., Olanow, C.W. (1998) The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann. Neurol., 44, S189-196.
265. Marsden, C.D., Parkes, J.D. (1976) "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet, 1, 292-296.
266. Marsden, C.D., Parkes, J.D. (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet, 1, 345-349.
267. Martin, W.R., Ye, F.Q., Allen, P.S. (1998) Increasing striatal iron content associated with normal aging. Mov. Disord., 13, 281-286.
268. Martyn, C.N., Coggon, D.N., Inskip, H., Lacey, R.F., Young, W.F. (1997) Aluminum concentrations in drinking water and risk of Alzheimer's disease. Epidemiology, 8, 281-286.
269. Mash, D.C., Ouyang, Q., Pablo, J., Basile, M., Izenwasser, S., Lieberman, A., Perrin, R.J. (2003) Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. J. Neurosci., 23, 2564-2571.
270. Maskri, L., Zhu, X., Fritzen, S., Kuhn, K., Ullmer, C., Engels, P., Andriske, M., Stichel, C.C., Lubbert, H. (2004) Influence of different promoters on the expression pattern of mutated human alpha-synuclein in transgenic mice. Neurodegener. Dis., 1, 255-265.
271. Mastakov, M.Y., Baer, K., Symes, C.W., Leichtlein, C.B., Kotin, R.M., During, M.J. (2002) Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J. Virol., 76, 8446-8454.
272. Masuda, T., Hida, H., Kanda, Y., Aihara, N., Ohta, K., Yamada, K., Nishino, H. (2007) Oral administration of metal chelator ameliorates motor dysfunction after a small hemorrhage near the internal capsule in rat. J. Neurosci. Res., 85, 213-222.
273. Matsumine, H., Saito, M., Shimoda-Matsubayashi, S., Tanaka, H., Ishikawa, A., Nakagawa-Hattori, Y., Yokochi, M., Kobayashi, T., Igarashi, S., Takano, H., Sanpei, K., Koike, R., Mori, H., Kondo, T., Mizutani, Y., Schaffer, A.A., Yamamura, Y., Nakamura, S., Kuzuhara, S., Tsuji, S., Mizuno, Y. (1997) Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am. J. Hum. Genet., 60, 588-596.
274. Maynard, C.J., Cappai, R., Volitakis, I., Cherny, R.A., White, A.R., Beyreuther, K., Masters, C.L., Bush, A.I., Li, Q.X. (2002) Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem., 277, 44670-44676.
275. McCormack, A.L., Atienza, J.G., Johnston, L.C., Andersen, J.K., Vu, S., Di Monte, D.A. (2005) Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J. Neurochem., 93, 1030-1037.
276. McCormack, A.L., Thiruchelvam, M., Manning-Bog, A.B., Thiffault, C., Langston, J.W., Cory-Slechta, D.A., Di Monte, D.A. (2002) Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis., 10, 119-127.
277. McCown, T.J., Xiao, X., Li, J., Breese, G.R., Samulski, R.J. (1996) Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res., 713, 99-107.
278. McNaught, K.S., Belizaire, R., Isacson, O., Jenner, P., Olanow, C.W. (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol., 179, 38-46.
279. McNaught, K.S., Bjorklund, L.M., Belizaire, R., Isacson, O., Jenner, P., Olanow, C.W. (2002) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport, 13, 1437-1441.
280. McNaught, K.S., Mytilineou, C., Jnobaptiste, R., Yabut, J., Shashidharan, P., Jennert, P., Olanow, C.W. (2002) Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem., 81, 301-306.
281. McNaught, K.S., Perl, D.P., Brownell, A.L., Olanow, C.W. (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol., 56, 149-162.
282. McNaught, K.S., Shashidharan, P., Perl, D.P., Jenner, P., Olanow, C.W. (2002) Aggresome-related biogenesis of Lewy bodies. Eur. J. Neurosci., 16, 2136-2148.
283. Meglio, L., Oteiza, P.I. (1999) Aluminum enhances melanin-induced lipid peroxidation. Neurochem. Res., 24, 1001-1008.
284. Melo, T.M., Larsen, C., White, L.R., Aasly, J., Sjobakk, T.E., Flaten, T.P., Sonnewald, U., Syversen, T. (2003) Manganese, copper, and zinc in cerebrospinal fluid from patients with multiple sclerosis. Biol. Trace Elem. Res., 93, 1-8.
285. Mendez-Alvarez, E., Soto-Otero, R., Hermida-Ameijeiras, A., Lopez-Real, A.M., Labandeira-Garcia, J.L. (2002) Effects of aluminum and zinc on the oxidative stress caused by 6-hydroxydopamine autoxidation: relevance for the pathogenesis of Parkinson's disease. Biochim. Biophys. Acta, 1586, 155-168.
286. Menzies, F.M., Yenisetti, S.C., Min, K.T. (2005) Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress. Curr. Biol., 15, 1578-1582.
287. Meredith, G.E., Halliday, G.M., Totterdell, S. (2004) A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat. Disord., 10, 191-202.
288. Meulener, M.C., Xu, K., Thomson, L., Ischiropoulos, H., Bonini, N.M. (2006) Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc. Natl. Acad. Sci. USA, 103, 12517-12522.
289. Middleton, E., Jr. (1998) Effect of plant flavonoids on immune and inflammatory cell function. Adv. Exp. Med. Biol., 439, 175-182.
290. Momose, Y., Murata, M., Kobayashi, K., Tachikawa, M., Nakabayashi, Y., Kanazawa, I., Toda, T. (2002) Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol., 51, 133-136.
291. Moon, Y., Lee, K.H., Park, J.H., Geum, D., Kim, K. (2005) Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J. Neurochem., 93, 1199-1208.
292. Moore, P.B., Day, J.P., Taylor, G.A., Ferrier, I.N., Fifield, L.K., Edwardson, J.A. (2000) Absorption of aluminium-26 in Alzheimer's disease, measured using accelerator mass spectrometry. Dement. Geriatr. Cogn. Disord., 11, 66-69.
293. Morris, C.M., Candy, J.M., Oakley, A.E., Taylor, G.A., Mountfort, S., Bishop, H., Ward, M.K., Bloxham, C.A., Edwardson, J.A. (1989) Comparison of the regional distribution of transferrin receptors and aluminium in the forebrain of chronic renal dialysis patients. J. Neurol. Sci., 94, 295-306.
294. Morris, C.M., Keith, A.B., Edwardson, J.A., Pullen, R.G. (1992) Uptake and distribution of iron and transferrin in the adult rat brain. J. Neurochem., 59, 300-306.
295. Morrish, P.K., Rakshi, J.S., Bailey, D.L., Sawle, G.V., Brooks, D.J. (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with 18Fdopa PET. J. Neurol. Neurosurg. Psychiatry, 64, 314-319.
296. Mosharov, E.V., Staal, R.G., Bove, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K.E., Moore, C.M., Troyer, M.D., Edwards, R.H., Przedborski, S., Sulzer, D. (2006) Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci., 26, 9304-9311.
297. Muenter, M.D., Forno, L.S., Hornykiewicz, O., Kish, S.J., Maraganore, D.M., Caselli, R.J., Okazaki, H., Howard, F.M., Jr., Snow, B.J., Calne, D.B. (1998) Hereditary form of parkinsonism--dementia. Ann. Neurol., 43, 768-781.
298. Muller, T., Hefter, H., Hueber, R., Jost, W.H., Leenders, K.L., Odin, P., Schwarz, J. (2004) Is levodopa toxic? J. Neurol., 251 (Suppl 6), VI/44-46.
299. Mytilineou, C., McNaught, K.S., Shashidharan, P., Yabut, J., Baptiste, R.J., Parnandi, A., Olanow, C.W. (2004) Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. J. Neural. Transm, 111, 1237-1251.
300. Narayanan, V., Scarlata, S. (2001) Membrane binding and self-association of alpha-synucleins. Biochemistry, 40, 9927-9934.
301. Narhi, L., Wood, S.J., Steavenson, S., Jiang, Y., Wu, G.M., Anafi, D., Kaufman, S.A., Martin, F., Sitney, K., Denis, P., Louis, J.C., Wypych, J., Biere, A.L., Citron, M. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem., 274, 9843-9846.
302. Noack, H., Kube, U., Augustin, W. (1994) Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. Free Radic. Res., 20, 375-386.
303. Norris, E.H., Giasson, B.I., Ischiropoulos, H., Lee, V.M. (2003) Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J. Biol. Chem., 278, 27230-27240.
304. Obeso, J.A., Rodriguez-Oroz, M., Marin, C., Alonso, F., Zamarbide, I., Lanciego, J.L., Rodriguez-Diaz, M. (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology, 62, S17-30.
305. Obeso, J.A., Rodriguez-Oroz, M.C., Lanciego, J.L., Rodriguez Diaz, M. (2004) How does Parkinson's disease begin? The role of compensatory mechanisms. Trends Neurosci., 27, 125-127; author reply 127-128.
306. Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., Lanciego, J.L., Artieda, J., Gonzalo, N., Olanow, C.W. (2000) Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci., 23, S8-19.
307. Odunze, I.N., Klaidman, L.K., Adams, J.D., Jr. (1990) MPTP toxicity in the mouse brain and vitamin E. Neurosci. Lett., 108, 346-349.
308. Ogasahara, S., Yorifuji, S., Nishikawa, Y., Takahashi, M., Wada, K., Hazama, T., Nakamura, Y., Hashimoto, S., Kono, N., Tarui, S. (1985) Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology, 35, 372-377.
309. Ohshima, H., Gilibert, I., Bianchini, F. (1999) Induction of DNA strand breakage and base oxidation by nitroxyl anion through hydroxyl radical production. Free Radic. Biol. Med., 26, 1305-1313.
310. Oikawa, S., Hirosawa, I., Tada-Oikawa, S., Furukawa, A., Nishiura, K., Kawanishi, S. (2006) Mechanism for manganese enhancement of dopamine-induced oxidative DNA damage and neuronal cell death. Free Radic. Biol. Med., 41, 748-756.
311. Olanow, C.W., Goetz, C.G., Kordower, J.H., Stoessl, A.J., Sossi, V., Brin, M.F., Shannon, K.M., Nauert, G.M., Perl, D.P., Godbold, J., Freeman, T.B. (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol., 54, 403-414.
312. Ossowska, K., Wardas, J., Smialowska, M., Kuter, K., Lenda, T., Wieronska, J.M., Zieba, B., Nowak, P., Dabrowska, J., Bortel, A., Kwiecinski, A., Wolfarth, S. (2005) A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease? Eur. J. Neurosci., 22, 1294-1304.
313. Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J.M., Farer, M., Wolozin, B. (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci., 20, 6048-6054.
314. Pacifici, R.E., Kono, Y., Davies, K.J. (1993) Hydrophobicity as the signal for selective degradation of hydroxyl radical-modified hemoglobin by the multicatalytic proteinase complex, proteasome. J. Biol. Chem., 268, 15405-15411.
315. Paik, S.R., Shin, H.J., Lee, J.H., Chang, C.S., Kim, J. (1999) Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem. J., 340 (Pt 3), 821-828.
316. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N., Johnson, J., Martinez, J.R., Nicholl, D., Carrera, I.M., Pena, A.S., de Silva, R., Lees, A., Marti-Masso, J.F., Perez-Tur, J., Wood, N.W., Singleton, A.B. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 44, 595-600.
317. Palhagen, S., Heinonen, E., Hagglund, J., Kaugesaar, T., Maki-Ikola, O., Palm, R. (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology, 66, 1200-1206.
318. Parenti, M., Rusconi, L., Cappabianca, V., Parati, E.A., Groppetti, A. (1988) Role of dopamine in manganese neurotoxicity. Brain Res., 473, 236-240.
319. Parish, C.L., Drago, J., Stanic, D., Borrelli, E., Finkelstein, D.I., Horne, M.K. (2005) Haloperidol treatment reverses behavioural and anatomical changes in cocaine-dependent mice. Neurobiol. Dis., 19, 301-311.
320. Park, J., Kim, S.Y., Cha, G.H., Lee, S.B., Kim, S., Chung, J. (2005) Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. Gene, 361, 133-139.
321. Patel, N.K., Heywood, P., O'Sullivan, K., McCarter, R., Love, S., Gill, S.S. (2003) Unilateral subthalamotomy in the treatment of Parkinson's disease. Brain, 126, 1136-1145.
322. Pearce, R.K., Owen, A., Daniel, S., Jenner, P., Marsden, C.D. (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural. Transm., 104, 661-677.
323. Pedersen, W.A., Cashman, N.R., Mattson, M.P. (1999) The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells. Exp. Neurol., 155, 1-10.
324. Perez, R.G., Waymire, J.C., Lin, E., Liu, J.J., Guo, F., Zigmond, M.J. (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci., 22, 3090-3099.
325. Perl, D.P. (2006) Exposure to aluminium and the subsequent development of a disorder with features of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 77, 811.
326. Perl, D.P., Gajdusek, D.C., Garruto, R.M., Yanagihara, R.T., Gibbs, C.J. (1982) Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science, 217, 1053-1055.
327. Perry, T.L., Yong, V.W., Clavier, R.M., Jones, K., Wright, J.M., Foulks, J.G., Wall, R.A. (1985) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett., 60, 109-114.
328. Perry, T.L., Yong, V.W., Hansen, S., Jones, K., Bergeron, C., Foulks, J.G., Wright, J.M. (1987) Alpha-tocopherol and betacarotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurol. Sci., 81, 321-331.
329. Piccardo, P., Yanagihara, R., Garruto, R.M., Gibbs, C.J., Jr., Gajdusek, D.C. (1988) Histochemical and X-ray microanalytical localization of aluminum in amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Acta Neuropathol., 77, 1-4.
330. Pinero, D., Jones, B., Beard, J. (2001) Variations in dietary iron alter behavior in developing rats. J. Nut., 131, 311-318.
331. Pitkanen-Arsiola, T., Tillman, J.E., Gu, G., Yuan, J., Roberts, R.L., Wantroba, M., Coetzee, G.A., Cookson, M.S., Kasper, S. (2006) Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability. Prostate, 66, 1177-1193.
332. Polizzi, S., Pira, E., Ferrara, M., Bugiani, M., Papaleo, A., Albera, R., Palmi, S. (2002) Neurotoxic effects of aluminium among foundry workers and Alzheimer's disease. Neurotoxicology, 23, 761-774.
333. Polymeropoulos, M.H., Higgins, J.J., Golbe, L.I., Johnson, W.G., Ide, S.E., Di Iorio, G., Sanges, G., Stenroos, E.S., Pho, L.T., Schaffer, A.A., Lazzarini, A.M., Nussbaum, R.L., Duvoisin, R.C. (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science, 274, 1197-1199.
334. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I., Nussbaum, R.L. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
335. Przedborski, S., Kostic, V., Jackson-Lewis, V., Naini, A.B., Simonetti, S., Fahn, S., Carlson, E., Epstein, C.J., Cadet, J.L. (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci., 12, 1658-1667.
336. Puglielli, L., Friedlich, A.L., Setchell, K.D., Nagano, S., Opazo, C., Cherny, R.A., Barnham, K.J., Wade, J.D., Melov, S., Kovacs, D.M., Bush, A.I. (2005) Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J. Clin. Invest., 115, 2556-2563.
337. Racette, B.A., Tabbal, S.D., Jennings, D., Good, L., Perlmutter, J.S., Evanoff, B. (2005) Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. Neurology, 64, 230-235.
338. Radi, R., Beckman, J.S., Bush, K.M., Freeman, B.A. (1991) Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys., 288, 481-487.
339. Reinheckel, T., Sitte, N., Ullrich, O., Kuckelkorn, U., Davies, K.J., Grune, T. (1998) Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem. J., 335 (Pt 3), 637-642.
340. Ren, Y.R., Nishida, Y., Yoshimi, K., Yasuda, T., Jishage, K., Uchihara, T., Yokota, T., Mizuno, Y., Mochizuki, H. (2006) Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain. J. Neurochem., 98, 1810-1816.
341. Richardson, D.R., Mouralian, C., Ponka, P., Becker, E. (2001) Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim. Biophys. Acta, 1536, 133-140.
342. Richter, F., Hamann, M., Richter, A. (2007) Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice. J. Neurosci. Res., 85, 681-691.
343. Ritchie, C.W., Bush, A.I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.X., Tammer, A., Carrington, D., Mavros, C., Volitakis, I., Xilinas, M., Ames, D., Davis, S., Beyreuther, K., Tanzi, R.E., Masters, C.L. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol., 60, 1685-1691.
344. Rogaeva, E., Johnson, J., Lang, A.E., Gulick, C., Gwinn-Hardy, K., Kawarai, T., Sato, C., Morgan, A., Werner, J., Nussbaum, R., Petit, A., Okun, M.S., McInerney, A., Mandel, R., Groen, J.L., Fernandez, H.H., Postuma, R., Foote, K.D., Salehi-Rad, S., Liang, Y., Reimsnider, S., Tandon, A., Hardy, J., St George-Hyslop, P., Singleton, A.B. (2004) Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch. Neurol., 61, 1898-1904.
345. Rondeau, V., Commenges, D., Jacqmin-Gadda, H., Dartigues, J.F. (2000) Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study. Am. J. Epidemiol., 152, 59-66.
346. Roy, N.S., Cleren, C., Singh, S.K., Yang, L., Beal, M.F., Goldman, S.A. (2006) Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med., 12, 1259-1268.
347. Saigoh, K., Wang, Y.L., Suh, J.G., Yamanishi, T., Sakai, Y., Kiyosawa, H., Harada, T., Ichihara, N., Wakana, S., Kikuchi, T., Wada, K. (1999) Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet., 23, 47-51.
348. Salah, N., Miller, N.J., Paganga, G., Tijburg, L., Bolwell, G.P., Rice-Evans, C. (1995) Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch. Biochem. Biophys., 322, 339-346.
349. Saper, C.B., Petito, C.K. (1982) Correspondence of melanin-pigmented neurons in human brain with A1-A14 catecholamine cell groups. Brain, 105, 87-101.
350. Sapru, M.K., Yates, J.W., Hogan, S., Jiang, L., Halter, J., Bohn, M.C. (2006) Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol., 198, 382-390.
351. Satoh, J., Kuroda, Y. (2001) A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J. Neurol. Sci., 189, 113-117.
352. Sawada, H., Ibi, M., Kihara, T., Urushitani, M., Akaike, A., Kimura, J., Shimohama, S. (1998) Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol., 44, 110-119.
353. Scheider, W.L., Hershey, L.A., Vena, J.E., Holmlund, T., Marshall, J.R., Freudenheim (1997) Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov. Disord., 12, 190-196.
354. Schober, A. (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res., 318, 215-224.
355. Schwarting, R.K., Huston, J.P. (1996) Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol., 49, 215-266.
356. Sestili, P., Piedimonte, G., Cattabeni, F., Cantoni, O. (1986) Induction of DNA breakage and suppression of DNA synthesis by the OH radical generated in a Fenton-like reaction. Biochem. Int., 12, 493-501.
357. Shachar, D.B., Kahana, N., Kampel, V., Warshawsky, A., Youdim, M.B. (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology, 46, 254-263.
358. Shen, X.M., Dryhurst, G. (1998) Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity. Chem. Res. Toxicol., 11, 824-837.
359. Sherer, T.B., Betarbet, R., Stout, A.K., Lund, S., Baptista, M., Panov, A.V., Cookson, M.R., Greenamyre, J.T. (2002) An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci., 22, 7006-7015.
360. Sherer, T.B., Kim, J.H., Betarbet, R., Greenamyre, J.T. (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol., 179, 9-16.
361. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., Suzuki, T. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet., 25, 302-305.
362. Shimura, H., Schlossmacher, M.G., Hattori, N., Frosch, M.P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K.S., Selkoe, D.J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science, 293, 263-269.
363. Shinotoh, H., Snow, B.J., Chu, N.S., Huang, C.C., Lu, C.S., Lee, C., Takahashi, H., Calne, D.B. (1997) Presynaptic and postsynaptic striatal dopaminergic function in patients with manganese intoxication: a positron emission tomography study. Neurology, 48, 1053-1056.
364. Shults, C.W., Oakes, D., Kieburtz, K., Beal, M.F., Haas, R., Plumb, S., Juncos, J.L., Nutt, J., Shoulson, I., Carter, J., Kompoliti, K., Perlmutter, J.S., Reich, S., Stern, M., Watts, R.L., Kurlan, R., Molho, E., Harrison, M., Lew, M. (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol., 59, 1541-1550.
365. Sian, J., Dexter, D.T., Lees, A.J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P., Marsden, C.D. (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol., 36, 348-355.
366. Siderowf, A., Stern, M. (2006) Clinical trials with rasagiline: evidence for short-term and long-term effects. Neurology, 66, S80-88.
367. Sies, H., Stahl, W., Sundquist, A.R. (1992) Antioxidant functions of vitamins. Vitamins E and C, beta-carotene, and other carotenoids. Ann. N. Y. Acad. Sci., 669, 7-20.
368. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M.R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., Gwinn-Hardy, K. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
369. Sjogren, B., Iregren, A., Frech, W., Hagman, M., Johansson, L., Tesarz, M., Wennberg, A. (1996) Effects on the nervous system among welders exposed to aluminium and manganese. Occup. Environ. Med., 53, 32-40.
370. Slevin, J.T., Gerhardt, G.A., Smith, C.D., Gash, D.M., Kryscio, R., Young, B. (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg., 102, 216-222.
371. Smith, A.D., Kozlowski, D.A., Bohn, M.C., Zigmond, M.J. (2005) Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats. Exp. Neurol., 193, 420-426.
372. Smith, M.P., Cass, W.A. (2006) GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease. Neurosci. Lett., 412(3), 259-263.
373. Sobotka, T.J., Whittaker, P., Sobotka, J.M., Brodie, R.E., Quander, D.Y., Robl, M., Bryant, M., Barton, C.N. (1996) Neurobehavioral dysfunctions associated with dietary iron overload. Physiol. Behav., 59, 213-219.
374. Sofic, E., Lange, K.W., Jellinger, K., Riederer, P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett., 142, 128-130.
375. Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G.P., Hebenstreit, G., Youdim, M.B. (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural. Transm., 74, 199-205.
376. Somayajulu, M., McCarthy, S., Hung, M., Sikorska, M., Borowy-Borowski, H., Pandey, S. (2005) Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10. Neurobiol. Dis., 18, 618-627.
377. Sonsalla, P.K., Jochnowitz, N.D., Zeevalk, G.D., Oostveen, J.A., Hall, E.D. (1996) Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res., 738, 172-175.
378. Souza, J.M., Giasson, B.I., Chen, Q., Lee, V.M., Ischiropoulos, H. (2000) Dityrosine cross-linking promotes formation of stable alpha- synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem., 275, 18344-18349.
379. Sparks, D.L., Lochhead, J., Horstman, D., Wagoner, T., Martin, T. (2002) Water quality has a pronounced effect on cholesterol-induced accumulation of Alzheimer amyloid beta (Abeta) in rabbit brain. J. Alzheimers Dis., 4, 523-529.
380. Spiegel, J., Hellwig, D., Samnick, S., Jost, W., Mollers, M.O., Fassbender, K., Kirsch, C.M., Dillmann, U. (2007) Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J. Neural. Transm., 114, 331-335.
381. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
382. Spira, P.J., Sharpe, D.M., Halliday, G., Cavanagh, J., Nicholson, G.A. (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol., 49, 313-319.
383. Stanic, D., Finkelstein, D.I., Bourke, D.W., Drago, J., Horne, M.K. (2003) Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur. J. Neurosci., 18, 1175-1188.
384. Stefani, A., Fedele, E., Galati, S., Pepicelli, O., Frasca, S., Pierantozzi, M., Peppe, A., Brusa, L., Orlacchio, A., Hainsworth, A.H., Gattoni, G., Stanzione, P., Bernardi, G., Raiteri, M., Mazzone, P. (2005) Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients. Ann. Neurol., 57, 448-452.
385. Stefanova, N., Kollensperger, M., Hainzer, M., Cenci, A., Poewe, W., Wenning, G.K. (2007) High dose levodopa therapy is not toxic in multiple system atrophy: experimental evidence. Mov. Disord., 22, 969-973.
386. Storch, A., Jost, W.H., Vieregge, P., Spiegel, J., Greulich, W., Durner, J., Muller, T., Kupsch, A., Henningsen, H., Oertel, W.H., Fuchs, G., Kuhn, W., Niklowitz, P., Koch, R., Herting, B., Reichmann, H. (2007) Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch. Neurol., 64, 938-944.
387. Storch, A., Paul, G., Csete, M., Boehm, B.O., Carvey, P.M., Kupsch, A., Schwarz, J. (2001) Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp. Neurol., 170, 317-325.
388. Stover, N.P., Okun, M.S., Evatt, M.L., Raju, D.V., Bakay, R.A., Vitek, J.L. (2005) Stimulation of the subthalamic nucleus in a patient with Parkinson disease and essential tremor. Arch. Neurol., 62, 141-143.
389. Suh, J.G., Yamanishi, T., Matsui, K., Tanaka, K., Wada, K. (1995) Mapping of the gracile axonal dystrophy (gad) gene to a region between D5Mit197 and D5Mit113 on proximal mouse chromosome 5. Genomics, 27, 549-551.
390. Sulzer, D., Bogulavsky, J., Larsen, K.E., Behr, G., Karatekin, E., Kleinman, M.H., Turro, N., Krantz, D., Edwards, R.H., Greene, L.A., Zecca, L. (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. USA, 97, 11869-11874.
391. Szabo, C., Zingarelli, B., O'Connor, M., Salzman, A.L. (1996) DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc. Natl. Acad. Sci. USA, 93, 1753-1758.
392. Tabrizi, S.J., Orth, M., Wilkinson, J.M., Taanman, J.W., Warner, T.T., Cooper, J.M., Schapira, A.H. (2000) Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet, 9, 2683-2689.
393. Tan, E.K., Puong, K.Y., Fook-Chong, S., Chua, E., Shen, H., Yuen, Y., Pavanni, R., Wong, M.C., Puvan, K., Zhao, Y. (2006) Case-control study of UCHL1 S18Y variant in Parkinson's disease. Mov. Disord., 21, 1765-1768.
394. Tarohda, T., Ishida, Y., Kawai, K., Yamamoto, M., Amano, R. (2005) Regional distributions of manganese, iron, copper, and zinc in the brains of 6-hydroxydopamine-induced parkinsonian rats. Anal. Bioanal. Chem., 383, 224-234.
395. Tatton, N.A., Kish, S.J. (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience, 77, 1037-1048.
396. Taylor, G.A., Ferrier, I.N., McLoughlin, I.J., Fairbairn, A.F., McKeith, I.G., Lett, D., Edwardson, J.A. (1992) Gastrointestinal absorption of aluminium in Alzheimer's disease: response to aluminium citrate. Age Ageing, 21, 81-90.
397. Taylor, G.A., Moore, P.B., Ferrier, I.N., Tyrer, S.P., Edwardson, J.A. (1998) Gastrointestinal absorption of aluminium and citrate in man. J. Inorg. Biochem., 69, 165-169.
398. Teixeira, S., Siquet, C., Alves, C., Boal, I., Marques, M.P., Borges, F., Lima, J.L., Reis, S. (2005) Structure-property studies on the antioxidant activity of flavonoids present in diet. Free. Radic. Biol. Med., 39, 1099-1108.
399. Testa, C.M., Sherer, T.B., Greenamyre, J.T. (2005) Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. Mol. Brain Res., 134, 109-118.
400. Thomas, B., Beal, M.F. (2007) Parkinson's disease. Hum. Mol. Genet., 16(Spec No. 2), R183-194.
401. Toda, T., Momose, Y., Murata, M., Tamiya, G., Yamamoto, M., Hattori, N., Inoko, H. (2003) Toward identification of susceptibility genes for sporadic Parkinson's disease. J. Neurol., 250(Suppl 3), III40-43.
402. Toft, M., Myhre, R., Pielsticker, L., White, L.R., Aasly, J.O., Farrer, M.J. (2007) PINK1 mutation heterozygosity and the risk of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 78, 82-84.
403. Trulson, M.E., Cannon, M.S., Faegg, T.S., Raese, J.D. (1985) Effects of chronic methamphetamine on the nigral-striatal dopamine system in rat brain: tyrosine hydroxylase immunochemistry and quantitative light microscopic studies. Brain Res. Bull., 15, 569-577.
404. Turunen, M., Olsson, J., Dallner, G. (2004) Metabolism and function of coenzyme Q. Biochim. Biophys. Acta, 1660, 171-199.
405. Uchiyama, S., Shimizu, T., Shirasawa, T. (2006) CuZn-SOD deficiency causes ApoB degradation and induces hepatic lipid accumulation by impaired lipoprotein secretion in mice. J. Biol. Chem., 281, 31713-31719.
406. Uemura, E. (1984) Intranuclear aluminum accumulation in chronic animals with experimental neurofibrillary changes. Exp. Neurol., 85, 10-18.
407. Unoki, M., Nakamura, Y. (2001) Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene, 20, 4457-4465.
408. Uversky, V.N., Gillespie, J.R., Fink, A.L. (2000) Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins, 41, 415-427.
409. Uversky, V.N., Li, J., Fink, A.L. (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem., 276, 10737-10744.
410. Uversky, V.N., Li, J., Fink, A.L. (2001) Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett., 500, 105-108.
411. Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A.R., Healy, D.G., Albanese, A., Nussbaum, R., Gonzalez-Maldonado, R., Deller, T., Salvi, S., Cortelli, P., Gilks, W.P., Latchman, D.S., Harvey, R.J., Dallapiccola, B., Auburger, G., Wood, N.W. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304, 1158-1160.
412. van der Putten, H., Wiederhold, K.H., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W.P., Ruegg, M.A., Lin, S., Caroni, P., Sommer, B., Tolnay, M., Bilbe, G. (2000) Neuropathology in mice expressing human alpha-synuclein. J. Neurosci., 20, 6021-6029.
413. van Duijn, C.M., Dekker, M.C., Bonifati, V., Galjaard, R.J., Houwing-Duistermaat, J.J., Snijders, P.J., Testers, L., Breedveld, G.J., Horstink, M., Sandkuijl, L.A., van Swieten, J.C., Oostra, B.A., Heutink, P. (2001) Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am. J. Hum. Genet., 69, 629-634.
414. Vila, M., Vukosavic, S., Jackson-Lewis, V., Neystat, M., Jakowec, M., Przedborski, S. (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem., 74, 721-729.
415. Voges, D., Zwickl, P., Baumeister, W. (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Ann. Rev. Biochem., 68, 1015-1068.
416. Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., Kessler, J.C., Lansbury, P.T., Jr. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry, 40, 7812-7819.
417. Wagner, G.C., Jarvis, M.F., Carelli, R.M. (1985) Ascorbic acid reduces the dopamine depletion induced by MPTP. Neuropharmacology, 24, 1261-1262.
418. Walton-Hadlock, J.L. (2005) Levodopa and the progression of Parkinson's disease. N. Engl. J. Med., 352, 1386.
419. Wang, D., Qian, L., Xiong, H., Liu, J., Neckameyer, W.S., Oldham, S., Xia, K., Wang, J., Bodmer, R., Zhang, Z. (2006) Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc. Natl. Acad. Sci. USA, 103, 13520-13525.
420. Wang, F., Feng, X., Ma, J., Zou, H., Chan, P. (2006) A common A340T variant in PINK1 gene associated with late-onset Parkinson's disease in Chinese. Neurosci. Lett., 410, 121-125.
421. Wang, L., Muramatsu, S., Lu, Y., Ikeguchi, K., Fujimoto, K., Okada, T., Mizukami, H., Hanazono, Y., Kume, A., Urano, F., Ichinose, H., Nagatsu, T., Nakano, I., Ozawa, K. (2002) Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther., 9, 381-389.
422. Washbourne, P., McAllister, A.K. (2002) Techniques for gene transfer into neurons. Curr. Opin. Neurobiol., 12, 566-573.
423. Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A., Lansbury, P.T., Jr. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 35, 13709-13715.
424. Wesemann, W., Blaschke, S., Solbach, M., Grote, C., Clement, H.W., Riederer, P. (1994) Intranigral injected iron progressively reduces striatal dopamine metabolism. J. Neural. Transm. Park. Dis. Dement. Sect., 8, 209-214.
425. Wettstein, A., Aeppli, J., Gautschi, K., Peters, M. (1991) Failure to find a relationship between mnestic skills of octogenarians and aluminum in drinking water. Int. Arch. Occup. Environ. Health, 63, 97-103.
426. White, A.R., Reyes, R., Mercer, J.F., Camakaris, J., Zheng, H., Bush, A.I., Multhaup, G., Beyreuther, K., Masters, C.L., Cappai, R. (1999) Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res., 842, 439-444.
427. Widdowson, P.S., Farnworth, M.J., Simpson, M.G., Lock, E.A. (1996) Influence of age on the passage of paraquat through the blood-brain barrier in rats: a distribution and pathological examination. Hum. Exp. Toxicol., 15, 231-236.
428. Wilkins, S., Masters, C.L., Bush, A.I., Cherny, R.A., Finkelstein, D.I. (2008) Cliquinol protects against cell death in Parkinson's disease models in vivo and in vitro. In: Groenewegen, H. Ed, Advances in Behavioral Biology. IBAGS IX. New York, Springer.
429. Winkler, C., Kirik, D., Bjorklund, A., Cenci, M.A. (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis., 10, 165-186.
430. Wintermeyer, P., Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Berg, D., Becker, G., Leroy, E., Polymeropoulos, M., Berger, K., Przuntek, H., Schols, L., Epplen, J.T., Riess, O. (2000) Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport, 11, 2079-2082.
431. Wolters, E.C., Francot, C., Bergmans, P., Winogrodzka, A., Booij, J., Berendse, H.W., Stoof, J.C. (2000) Preclinical (premotor) Parkinson's disease. J. Neurol., 247(Suppl 2), II103-109.
432. Wolters, E.C., Huang, C.C., Clark, C., Peppard, R.F., Okada, J., Chu, N.S., Adam, M.J., Ruth, T.J., Li, D., Calne, D.B. (1989) Positron emission tomography in manganese intoxication. Ann. Neurol., 26, 647-651.
433. Wong, C.S., Kwok, J.C., Richardson, D.R. (2004) PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. Biochim. Biophys. Acta, 1739, 70-80.
434. Yamada, M., Mizuno, Y., Mochizuki, H. (2005) Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum. Gene Ther., 16, 262-270.
435. Yang, Y., Gehrke, S., Imai, Y., Huang, Z., Ouyang, Y., Wang, J.W., Yang, L., Beal, M.F., Vogel, H., Lu, B. (2006) Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. USA, 103, 10793-10798.
436. Yoo, M.S., Chun, H.S., Son, J.J., DeGiorgio, L.A., Kim, D.J., Peng, C., Son, J.H. (2003) Oxidative stress regulated genes in nigral dopaminergic neuronal cells: correlation with the known pathology in Parkinson's disease. Brain Res. Mol. Brain Res., 110, 76-84.
437. Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E.R., Mizuno, Y. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA, 93, 2696-2701.
438. Youdim, M.B., Stephenson, G., Ben Shachar, D. (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci., 1012, 306-325.
439. Yuan, H., Sarre, S., Ebinger, G., Michotte, Y. (2005) Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J. Neurosci. Methods, 144, 35-45.
440. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Munoz, D.G., de Yebenes, J.G. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 55, 164-173.
441. Zecca, L., Pietra, R., Goj, C., Mecacci, C., Radice, D., Sabbioni, E. (1994) Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J. Neurochem., 62, 1097-1101.
442. Zecca, L., Swartz, H.M. (1993) Total and paramagnetic metals in human substantia nigra and its neuromelanin. J. Neural. Transm. Park. Dis. Dement. Sect., 5, 203-213.
443. Zhang, J., Graham, D.G., Montine, T.J., Ho, Y.S. (2000) Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J. Neuropathol. Exp. Neurol., 59, 53-61.
444. Zhang, J., Hattori, N., Leroy, E., Morris, H.R., Kubo, S., Kobayashi, T., Wood, N.W., Polymeropoulos, M.H., Mizuno, Y. (2000) Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat. Disord., 6, 195-197.
445. Zhang, J., Perry, G., Smith, M.A., Robertson, D., Olson, S.J., Graham, D.G., Montine, T.J. (1999) Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol., 154, 1423-1429.
446. Zhang, L., Shimoji, M., Thomas, B., Moore, D.J., Yu, S.W., Marupudi, N.I., Torp, R., Torgner, I.A., Ottersen, O.P., Dawson, T.M., Dawson, V.L. (2005) Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mo.l Genet., 14, 2063-2073.
447. Zhang, S.M., Hernan, M.A., Chen, H., Spiegelman, D., Willett, W.C., Ascherio, A. (2002) Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology, 59, 1161-1169.
448. Zhang, X., Xie, W., Qu, S., Pan, T., Wang, X., Le, W. (2005) Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun., 333, 544-549.
449. Zheng, H., Gal, S., Weiner, L.M., Bar-Am, O., Warshawsky, A., Fridkin, M., Youdim, M.B. (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem., 95, 68-78.
450. Zheng, J.S., Tang, L.L., Zheng, S.S., Zhan, R.Y., Zhou, Y.Q., Goudreau, J., Kaufman, D., Chen, A.F. (2005) Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease. Brain Res. Mol. Brain Res., 134, 155-161.
451. Zhou, W., Schaack, J., Zawada, W.M., Freed, C.R. (2002) Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res., 926, 42-50.
452. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., Stoessl, A.J., Pfeiffer, R.F., Patenge, N., Carbajal, I.C., Vieregge, P., Asmus, F., Muller-Myhsok, B., Dickson, D.W., Meitinger, T., Strom, T.M., Wszolek, Z.K., Gasser, T. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601-607.
453. Zou, L., Jankovic, J., Rowe, D.B., Xie, W., Appel, S.H., Le, W. (1999) Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci., 64, 1275-1285.